Celltrion Sees Sales Dip In Q3
As Company Sees Pro-Biosimilar Policies Offering A Boost In US
South Korea’s Celltrion delivered a relatively weak quarter in Q3, with a 26.9% drop in revenues despite robust sales of Truxima (rituximab) and Remsima (infliximab). The company also voiced confidence in pro-biosimilar policies introduced by the Biden administration in the US.
